Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25669981 | 0.79 | TLR7 (0.32) | — | |
| SCHEMBL28533907 | 0.78 | ALDH1A1 (0.32) | ALDH1A1CYP1A2CYP2C9CYP2C19MAPK1 | |
| SCHEMBL20970324 | 0.76 | NAAA (0.32) | NAAAALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL6937537 | 0.76 | LMNA (0.33) | TSHRALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2373255 | 0.76 | HCAR2 (0.30) | — | |
| SCHEMBL790706 | 0.76 | — | — | |
| SCHEMBL16619821 | 0.75 | NAAA (0.32) | NAAA | |
| SCHEMBL25667981 | 0.75 | APLNR (0.46) | — | |
| SCHEMBL28128988 | 0.74 | TSHR (0.35) | TSHRALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL1355692 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020037873-A1 | Biologically active phosphotriester-type compounds | CENTRE NATIONAL DE LA RECHERCH SIENTIFIQUE | 2002-03-28 | — | — | US | claimed |
| US-5849905-A | Biologically active phosphotriester-type nucleosides and methods for preparing same | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1998-12-15 | — | — | US | claimed |
| US-5770725-A | USES NOVEL GROUP, CHARACTERIZED BY THE PRESENCE OF-S-S-AND/OR S-C=Z (Z=O OR S) ENZYME LABILE BONDS WHICH LEADS, AFTER ENZYMATIC ACTIVATION, TO THE FORMATION OF UNSTABLE INTERMEDIATE WHICH RELEASES MONOPHOSPHATE OR MONOPHOSPHONATE | CENTER NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1998-06-23 | — | — | US | claimed |
| WO-1998011121-A1 | BIOLOGICALLY ACTIVE PHOSPHOTRIESTER-TYPE COMPOUNDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1998-03-19 | — | — | WO | claimed |
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | ARAXES PHARMA LLC (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | ARAXES PHARMA LLC (US) | 2023-06-29 | — | — | US | disclosed |
| CN-116014240-A | Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery using same | 三菱化学株式会社 | 2023-04-25 | — | — | CN | disclosed |
| WO-2023274383-A1 | KRAS G12D INHIBITOR AND USE THEREOF | 上海迪诺医药科技有限公司 | 2023-01-05 | — | — | WO | disclosed |
| EP-2545055-B1 | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | KRAS, NRAS, HRAS | TSHR 2016/4885POLB 653/4885KDM1A 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.